{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T04:12:36Z","timestamp":1768536756567,"version":"3.49.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This update starts with an interesting series of children and adults with congenital myasthenic syndrome with a <jats:italic toggle=\"yes\">DOK7<\/jats:italic> variant. The next section is on autoimmune myasthenia gravis (MG) epidemiology, cost of care, and hospitalizations. A number of studies on the newer treatments are discussed including a phase 2 trial of nipocalimab and recommendations for using some of these drugs. A large trial emphasizing the negative effects of pyridostigmine in muscle-specific kinase MG is covered. A study on the incidence of taste disorders and alopecia in MG follows. The update ends with the topic of the burden of disease in MG and Lambert\u2013Eaton myasthenic syndrome.<\/jats:p>","DOI":"10.1097\/cnd.0000000000000504","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T17:00:10Z","timestamp":1731949210000},"page":"90-99","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["What Is in the Neuromuscular Junction Literature?"],"prefix":"10.1097","volume":"26","author":[{"given":"David","family":"Lacomis","sequence":"first","affiliation":[{"name":"Departments of Neurology and Pathology (Neuropathology), University of Pittsburgh School of Medicine, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250507","doi-asserted-by":"crossref","first-page":"e1770","DOI":"10.1212\/WNL.0000000000006478","article-title":"Congenital myasthenic syndromes in adult neurology clinic: a long road to diagnosis and therapy","volume":"91","author":"Kao","year":"2018","journal-title":"Neurology"},{"key":"R2-20250507","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1055\/s-0037-1602832","article-title":"The increasing genetic and phenotypical diversity of congenital myasthenic syndromes","volume":"48","author":"McMacken","year":"2017","journal-title":"Neuropediatrics"},{"key":"R3-20250507","doi-asserted-by":"crossref","first-page":"e200155","DOI":"10.1212\/NXG.0000000000200155","article-title":"Homozygosity of a founder variant c.1508dupC in DOK7 causes congenital myasthenia with variable severity","volume":"10","author":"Palmio","year":"2024","journal-title":"Neurol Genet"},{"key":"R4-20250507","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2023-333097","article-title":"Epidemiology of myasthenia gravis in Denmark, Finland and Sweden: a population-based observational study","author":"Vissing","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R5-20250507","doi-asserted-by":"crossref","first-page":"e16233","DOI":"10.1111\/ene.16233","article-title":"The epidemiology and societal costs of myasthenia gravis in Norway: a non-interventional study using national registry data","volume":"31","author":"Engebretsen","year":"2024","journal-title":"Eur J Neurol"},{"key":"R6-20250507","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/mus.28077","article-title":"Epidemiology of seropositive myasthenia gravis in Sardinia: a population-based study in the district of Sassari","volume":"69","author":"Sechi","year":"2024","journal-title":"Muscle Nerve"},{"key":"R7-20250507","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mus.28006","article-title":"Incidence and prevalence of myasthenia gravis in the United States: a claims-based analysis","volume":"69","author":"Rodrigues","year":"2024","journal-title":"Muscle Nerve"},{"key":"R8-20250507","doi-asserted-by":"crossref","first-page":"809999","DOI":"10.3389\/fneur.2021.809999","article-title":"Real-world healthcare resource utilization and cost burden assessment for adults with generalized myasthenia gravis in the United States","volume":"12","author":"Phillips","year":"2021","journal-title":"Front Neurol"},{"key":"R9-20250507","doi-asserted-by":"crossref","first-page":"e207863","DOI":"10.1212\/WNL.0000000000207863","article-title":"Hospitalizations and mortality from myasthenia gravis: trends from 2 US national datasets","volume":"102","author":"Habib","year":"2024","journal-title":"Neurology"},{"key":"R10-20250507","doi-asserted-by":"crossref","first-page":"102366","DOI":"10.1016\/j.autrev.2019.102366","article-title":"Next-generation Fc receptor-targeting biologics for autoimmune diseases","volume":"18","author":"Zuercher","year":"2019","journal-title":"Autoimmun Rev."},{"key":"R11-20250507","doi-asserted-by":"crossref","first-page":"e207937","DOI":"10.1212\/WNL.0000000000207937","article-title":"Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 vivacity-MG study","volume":"102","author":"Antozzi","year":"2024","journal-title":"Neurology"},{"key":"R12-20250507","doi-asserted-by":"crossref","first-page":"e20020","DOI":"10.1212\/NXI.0000000000200220","article-title":"Functional signature of LRP4 antibodies in myasthenia gravis","volume":"11","author":"Chuquisana","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R13-20250507","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1007\/s00415-024-12209-3","article-title":"Improvement of fatigue in generalised myasthenia gravis with zilucoplan","volume":"271","author":"Weiss","year":"2024","journal-title":"J Neurol"},{"key":"R14-20250507","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol"},{"key":"R15-20250507","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2169\/internalmedicine.1893-23","article-title":"Serious bacterial Infections associated with eculizumab: a pharmacovigilance study","volume":"63","author":"Okusa","year":"2024","journal-title":"Intern Med"},{"key":"R16-20250507","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00415-024-12247-x","article-title":"The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis","volume":"271","author":"Li","year":"2024","journal-title":"J Neurol"},{"key":"R17-20250507","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol"},{"key":"R18-20250507","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/mus.28042","article-title":"Retrospective review of patients with myasthenia gravis switched from plasma exchange therapy to efgartigimod treatment","volume":"69","author":"Mehrabyan","year":"2024","journal-title":"Muscle Nerve"},{"key":"R19-20250507","doi-asserted-by":"crossref","first-page":"e16229","DOI":"10.1111\/ene.16229","article-title":"Generalized myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment","volume":"31","author":"Gilhus","year":"2024","journal-title":"Eur J Neurol"},{"key":"R20-20250507","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/mus.28038","article-title":"How should newer therapeutic agents be incorporated into the treatment of patients with myasthenia gravis?","volume":"69","author":"Gwathmey","year":"2024","journal-title":"Muscle Nerve"},{"key":"R21-20250507","doi-asserted-by":"crossref","first-page":"e16189","DOI":"10.1111\/ene.16189","article-title":"Efgartigimod in generalized myasthenia gravis: a real-life experience at a national reference center","volume":"31","author":"Frangiamore","year":"2024","journal-title":"Eur J Neurol"},{"key":"R22-20250507","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol"},{"key":"R23-20250507","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.nmd.2022.09.002","article-title":"The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study","volume":"32","author":"Remijn-Nelissen","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"R24-20250507","doi-asserted-by":"crossref","first-page":"123047","DOI":"10.1016\/j.jns.2024.123047","article-title":"Acetylcholinesterase inhibitors are ineffective in MuSK-antibody positive myasthenia gravis: results of a study on 202 patients","volume":"461","author":"Ricciardi","year":"2024","journal-title":"J Neurol Sci"},{"key":"R25-20250507","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12883-024-03644-w","article-title":"Taste disorders and alopecia in myasthenia gravis","volume":"24","author":"Uzawa","year":"2024","journal-title":"BMC Neurol"},{"key":"R26-20250507","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1007\/s00415-024-12206-6","article-title":"Burden of disease in Lambert-Eaton myasthenic syndrome: taking the patient's perspective","volume":"271","author":"Lehnerer","year":"2024","journal-title":"J Neurol"},{"key":"R27-20250507","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","article-title":"Burden of disease in myasthenia gravis: taking the patient's perspective","volume":"269","author":"Lehnerer","year":"2022","journal-title":"J Neurol"},{"key":"R28-20250507","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s00103-012-1650-9","article-title":"The first wave of the German Health Interview and Examination Survey for Adults (DEGS1): sample design, response, weighting and representativeness [in German]","volume":"56","author":"Kamtsiuris","year":"2013","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"R29-20250507","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12883-024-03553-y","article-title":"Systematic review of the patient burden of generalised myasthenia gravis in Europe, the Middle East, and Africa","volume":"24","author":"McCallion","year":"2024","journal-title":"BMC Neurol"},{"key":"R30-20250507","doi-asserted-by":"crossref","first-page":"e16180","DOI":"10.1111\/ene.16180","article-title":"Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy","volume":"31","author":"Sacc\u00e0","year":"2024","journal-title":"Eur J Neurol"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T21:02:23Z","timestamp":1746651743000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000504","relation":{},"ISSN":["1522-0443","1537-1611"],"issn-type":[{"value":"1522-0443","type":"print"},{"value":"1537-1611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}